Syros begins Phase II clinical trial of SY-1425 to treat AML and MDS

US-based Syros Pharmaceuticals has initiated its Phase II clinical trial of SY-1425 by dosing the first patient suffering from relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news